$855 Million is the total value of Rock Springs Capital Management LP's 93 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| F113PS | New | COVIDIEN PLC | $30,173,000 | – | 295,000 | +100.0% | 3.53% | – |
| STJ | New | ST JUDE MED INC | $21,785,000 | – | 335,000 | +100.0% | 2.55% | – |
| XLV | New | SELECT SECTOR SPDR TRsbi healthcare | $9,573,000 | – | 140,000 | +100.0% | 1.12% | – |
| TRNX | New | TORNIER N V | $9,499,000 | – | 372,500 | +100.0% | 1.11% | – |
| SLXP | New | SALIX PHARMACEUTICALS INC | $8,908,000 | – | 77,500 | +100.0% | 1.04% | – |
| JUNO | New | JUNO THERAPEUTICS INC | $7,542,000 | – | 144,426 | +100.0% | 0.88% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $7,213,000 | – | 80,000 | +100.0% | 0.84% | – |
| PRAH | New | PRA HEALTH SCIENCES INC | $6,903,000 | – | 285,000 | +100.0% | 0.81% | – |
| STE | New | STERIS CORP | $5,253,000 | – | 81,000 | +100.0% | 0.61% | – |
| CNXR | New | CONNECTURE INC | $4,994,000 | – | 554,225 | +100.0% | 0.58% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS IN | $4,471,000 | – | 365,000 | +100.0% | 0.52% | – |
| FGEN | New | FIBROGEN INC | $4,137,000 | – | 151,300 | +100.0% | 0.48% | – |
| CHRS | New | COHERUS BIOSCIENCES INC | $3,918,000 | – | 240,051 | +100.0% | 0.46% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $3,692,000 | – | 9,000 | +100.0% | 0.43% | – |
| CSLT | New | CASTLIGHT HEALTH INCcl b | $3,044,000 | – | 260,200 | +100.0% | 0.36% | – |
| TRIV | New | TRIVASCULAR TECHNOLOGIES INC | $2,489,000 | – | 198,000 | +100.0% | 0.29% | – |
| BLUE | New | BLUEBIRD BIO INC | $2,293,000 | – | 25,000 | +100.0% | 0.27% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $1,895,000 | – | 28,000 | +100.0% | 0.22% | – |
| ADXS | New | ADVAXIS INC | $1,802,000 | – | 225,000 | +100.0% | 0.21% | – |
| DERM | New | DERMIRA INC | $1,581,000 | – | 87,274 | +100.0% | 0.18% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $806,000 | – | 35,000 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 43 | Q2 2024 | 4.0% |
| NEUROCRINE BIOSCIENCES INC | 42 | Q2 2024 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 42 | Q2 2024 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 42 | Q2 2024 | 2.4% |
| ACADIA HEALTHCARE COMPANY IN | 41 | Q2 2024 | 4.4% |
| ASCENDIS PHARMA A/S | 38 | Q2 2024 | 1.3% |
| BIOMARIN PHARMACEUTICAL INC | 38 | Q2 2024 | 1.3% |
| MACROGENICS INC | 38 | Q2 2024 | 0.5% |
| AMICUS THERAPEUTICS INC | 37 | Q2 2024 | 0.6% |
| ADAPTIMMUNE THERAPEUTICS PLC | 37 | Q2 2024 | 1.2% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Travere Therapeutics, Inc. | May 01, 2024 | 4,411,983 | 5.8% |
| Xilio Therapeutics, Inc. | April 05, 2024 | 3,003,259 | 8.7% |
| Aclaris Therapeutics, Inc. | February 14, 2024 | 2,998,495 | 4.2% |
| AGIOS PHARMACEUTICALS, INC. | February 14, 2024 | 2,152,173 | 3.8% |
| Gamida Cell Ltd.Sold out | February 14, 2024 | 0 | 0.0% |
| Immunocore Holdings plc | February 14, 2024 | 2,661,507 | 5.4% |
| Inozyme Pharma, Inc. | February 14, 2024 | 3,681,174 | 6.0% |
| Mereo BioPharma Group plc | February 14, 2024 | 39,919,255 | 5.7% |
| SPRUCE BIOSCIENCES, INC. | February 14, 2024 | 2,609,125 | 6.4% |
| Spyre Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.